The vulvovaginal candidiasis treatment market size is estimated to be USD 997.76 million in 2022 and is expected to witness a CAGR of 4.85% during the forecast period 2023-2033. Rise in the incidence of disease, advancements in R&D, novel approvals, and drug launches are some of the factors contributing to the market growth. Furthermore, surge in hospital-acquired infections, rise in healthcare spending, and improvements in healthcare infrastructure are other factors supporting the market growth. However, lack of awareness regarding the disease is expected to hinder the growth.

Rise in the incidence of disease is expected to propel the market growth during the projected period. Increase in the number of people with diabetes and surge in the incidence of antibiotic resistance are both contributing to the disease’s rising incidence. Nearly 75% of females who report experience the disease at least once in their lifetime are now affected by the VVC infection that is on the rise in the world. An NCBI article states that 9% of women report recurrent VVC cases and that 10-20% of women worldwide are affected by complicated VVC.

Advancements in R&D, novel approvals, and drug launches is predicted to fuel the market growth during the forecast period. For instance, the oral medication VIVJOA was approved by the FDA in August 2022. The antifungal medicine VIVJOA from Mycovia Pharmaceuticals specifically targets and inhibits fungus CYP5. The FDA approved BREXAFEMME (Ibrexafungerp), a novel medicine from Scynexis, Inc. that is indicated to treat VVC, in June 2021. The growth of the industry is predicted to be spurred by all of these launches.

Segmentation

By Drug Class

The market is categorized into nystatin, ketoconazole, clotrimazole, terconazole, fluconazole, terbinafine, others. In 2022, the fluconazole segment accounted for the highest revenue share due to its high efficiency. The fungus that is causing the infection is eliminated by fluconazole. The medication kills the fungus by rupturing the cell membrane and allowing the insides to escape. This eliminates the infection and relieves the symptoms. The clotrimazole segment is anticipated to dominate the global market throughout the forecast period due to due to the high effectiveness and widespread use of the medicine clotrimazole. Clotrimazole, an antimycotic agent, was initially registered in Germany in 1973 under the trade name Canesten. Among the top brands used to treat vulvovaginal candidiasis is still Canesten. Later, there were soft capsules (soft ovules), internal vaginal cream, and external cream available. Different formulations are available in the market under various brand names, including Mycoderm-C, Abzorb, and Candid-V.

By Route of Administration

The market is categorized into topical, oral, and intravenous. In the global market, the oral segment accounted for the largest revenue share in 2022 owing to the common & practical route of administration for azoles, high absorption, and use for anti-fungal medications. The most often prescribed medication for both treatment and maintenance therapy is oral fluconazole. In cases of recurrent VVC, it is also useful when used as a short-term therapy. The FDA recently approved two oral dosage regimes of VIVJOA (oteseconazole) to lower recurrent VVC occurrences. The topical segment is anticipated to expand at a steady CAGR during the course of the study. The market demand is boosted by a significant supply of topical products, including over-the-counter and prescription formulations. Clotrimazole cream, Miconazole cream, and Tioconazole ointment are available over-the-counter (OTC), although Butoconazole cream and Terconazole cream require a prescription. Additionally, econazole and nystatin, which have been available on the market for more than 30 years, are recommended as topical antifungals. According to IDSA recommendations, topical antifungal medications should be used to treat mild VVC.

By Distribution Channel

The market is segmented into online pharmacy, hospital pharmacy, and retail pharmacy. In 2022, the retail pharmacy segment accounted for the largest revenue share owing to the fact that medication assistance is required for both short-term and long-term disease treatment, control, and management. Both prescription and over-the-counter (OTC) medications are available on the market, therefore pharmacists play a crucial role by advising patients and gaining their trust. Most medications can be obtained easily from retail pharmacies, especially while receiving care at home. All of these factors are anticipated to support the segment’s expansion. The online pharmacy distribution channel segment is anticipated to expand significantly during the projection period due to convenience and other advantages including home delivery.

Regional Markets

In 2022, North America region accounted for the highest revenue in the vulvovaginal candidiasis treatment market and is expected to maintain its dominance during the forecast period. This is attributed to the strict regulations, growing government support for enhancing healthcare infrastructure, and the presence of major market competitors in the area.

Competitor Insights

Some of the key players operating in the vulvovaginal candidiasis treatment market are Pfizer, Inc., Basilea Pharmaceutica Ltd., Bayer AG., Mycovia Pharmaceuticals, Inc., Cadila Pharmaceuticals, Astellas Pharma Inc., Grupo Ferrer International S.A., Scynexis, Inc., and Bristol-Myers Squibb Company.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, in August 2022, the FDA approved Mycovia Pharmaceuticals’ VIVJOA, which was already authorized in some European, Asian, and Latin American nations, for the treatment of recurrent VVC in the United States.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including drug class, route of administration, and distribution channel from 2023 to 2033.

Report Scope:

Segmentation: Vulvovaginal Candidiasis Treatment Market Report 2022 – 2033

Drug Class (Revenue, USD Million), 2022 – 2033

• Nystatin
• Ketoconazole
• Clotrimazole
• Terconazole
• Fluconazole
• Terbinafine
• Others

Route of Administration (Revenue, USD Million), 2022 – 2033

• Topical
• Oral
• Intravenous

Distribution Channel (Revenue, USD Million), 2022 – 2033

• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA